Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2007

01-12-2007 | Letter

The protective side of progesterone

Authors: Gianluigi Ferretti, Alessandra Felici, Francesco Cognetti

Published in: Breast Cancer Research | Issue 6/2007

Login to get access

Excerpt

According to Jerry's commentary [1], exogenous oestrogen and progesterone potently inhibit tumorigenesis, representing an interesting strategy to prevent breast cancer, but we feel that the concerns noted by Jerry deserve further comment. …
Literature
1.
2.
Beral V, Million Women Study Collaborators: Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007, 369: 1703-1710. 10.1016/S0140-6736(07)60534-0.CrossRefPubMed
3.
Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM: Progesterone induces Apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIP(L) overexpression. J Cell Biochem. 2007, 102: 442-452. 10.1002/jcb.21304.CrossRefPubMed
4.
Beral V, Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14596-5.CrossRefPubMed
5.
Beral V, Bull D, Reeves G, Million Women Study Collaborators: Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005, 365: 1543-1551. 10.1016/S0140-6736(05)66455-0.CrossRefPubMed
Metadata
Title
The protective side of progesterone
Authors
Gianluigi Ferretti
Alessandra Felici
Francesco Cognetti
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1792

Other articles of this Issue 6/2007

Breast Cancer Research 6/2007 Go to the issue

Commentary

Adjuvant endocrine therapy for premenopausal women with early breast cancer

Research article

Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer

Letter

Are triple-negative tumours and basal-like breast cancer synonymous? Authors' response

Research article

Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases

Research article

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Research article

Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-α mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits